Comparisons of standard interval dosage and extended interval dosage groups on MS activity and NEDA
| SID | Total EID | EED | LED | VED | Within EID | |
|---|---|---|---|---|---|---|
| Participants (n) | 1080 | 894 | 246 | 269 | 379 | |
| Percentage with no radiological activity | 756/928 81% | 558/681 82% | 177/195* 91% | 114/142 80% | 267/344 78% | EED>LED |
| Percentage of patients with no clinical activity | 704/957 74% | 464/620 75% | 153/203* 75% | 121/146 83% | 190/271 70% | EED>LED, VED |
| Percentage of patients with zero combined activity (NEDA) | 507/819 62% | 373/476 78% | 134/192* 70% | 89/134 66% | 150/254 59% | EED>LED, VED |
Means and SDs (in parentheses).
(A) Comparisons in columns 2–5 are to SID group. Comparisons between the three EID groups (EED vs LED vs VED) are displayed in column 6.
*Indicates EID group differs from SID group at p<0.05.
Indicates EID group differs from SID group at 0.05<p<0.10.
EED, early extended dosing; EID, extended interval dosing; LED, late extended dosing; MS, multiple sclerosis; NEDA, no evidence of disease activity; SID, standard interval dosing; VED, variable extended dosing.